Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/516794 |
| _version_ | 1818740464857120768 |
|---|---|
| author | Zakaria Maat Kamran Mushtaq Mohamed A. Yassin |
| author_facet | Zakaria Maat Kamran Mushtaq Mohamed A. Yassin |
| author_sort | Zakaria Maat |
| collection | DOAJ |
| description | Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia. Common adverse reactions (>15%) in patients diagnosed with CP-CML include myelosuppression, fluid retention, and diarrhea. We report a 34-year-old Filipino female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for 2 months, which progressed to colitis. |
| first_indexed | 2024-12-18T01:41:09Z |
| format | Article |
| id | doaj.art-7fb3f050297a4c249b0e5b71cb52312b |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-18T01:41:09Z |
| publishDate | 2021-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-7fb3f050297a4c249b0e5b71cb52312b2022-12-21T21:25:19ZengKarger PublishersCase Reports in Oncology1662-65752021-10-011431441144610.1159/000516794516794Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case ReportZakaria Maat0Kamran Mushtaq1Mohamed A. Yassin2Department of Medical Education, Hamad Medical Corporation, Doha, QatarDepartment of Gastroenterology, Hamad Medical Corporation, Doha, QatarDepartment of Hematology and BMT, Hamad Medical Corporation, Doha, QatarDasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia. Common adverse reactions (>15%) in patients diagnosed with CP-CML include myelosuppression, fluid retention, and diarrhea. We report a 34-year-old Filipino female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for 2 months, which progressed to colitis.https://www.karger.com/Article/FullText/516794colitischronic myeloid leukemiadasatinib |
| spellingShingle | Zakaria Maat Kamran Mushtaq Mohamed A. Yassin Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report Case Reports in Oncology colitis chronic myeloid leukemia dasatinib |
| title | Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report |
| title_full | Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report |
| title_fullStr | Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report |
| title_full_unstemmed | Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report |
| title_short | Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report |
| title_sort | dasatinib induced colitis with rectal sparing in a patient with chronic myeloid leukemia chronic phase on dasatinib as an upfront therapy case report |
| topic | colitis chronic myeloid leukemia dasatinib |
| url | https://www.karger.com/Article/FullText/516794 |
| work_keys_str_mv | AT zakariamaat dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport AT kamranmushtaq dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport AT mohamedayassin dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport |